Topics
CNS Tumors | Treatment | Clinical trials | Overview
Home > Publications > Topics > CNS Tumors > Treatment > Clinical trials > Overview
*Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC,
Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K,
Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T,
Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D.
SPIRIT
2013 statement: defining standard protocol items for clinical
trials.
Ann
Intern Med. 2013 Feb 5;158(3):200-7. doi:
10.7326/0003-4819-158-3-201302050-00583. PMID:
23295957. Guidelines. ˍ
*Watanabe S, Nonaka T, Maeda M, Yamada M, Sugii N, Hashimoto K,
Takano S, Koyanagi T, Arakawa Y, Ishikawa E.
Recent
Status of Phase I Clinical Trials for Brain Tumors: A Regulatory
Science Study of Exploratory Efficacy Endpoints.
Ther
Innov Regul Sci. 2024 Mar 26. doi:
10.1007/s43441-024-00644-3. PMID:
38530629. Review; Meta-analysis. ˍ
*Butler M, Mehra M, Chandasir A, Kaoutzani L, Vale FL.
Analysis
of the discontinuation and nonpublication of neurooncological
randomized clinical trials.
Neurooncol
Adv. 2024 Aug 1;6(1):vdae136. doi:
10.1093/noajnl/vdae136. PMID:
39211519. Observational study. ˍ
Wen PY, Preusser M, Albert NL.
Design
and conduct of theranostic trials in neuro-oncology: Challenges
and opportunities.
Neuro
Oncol. 2024 Oct 5:noae162. doi:
10.1093/neuonc/noae162. PMID:
39368109. Review. ˍ